Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

New England Journal of Medicine, Journal Year: 2018, Volume and Issue: 379(20), P. 1926 - 1936

Published: Oct. 20, 2018

The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor palbociclib, in combination with fulvestrant therapy, prolongs progression-free survival among patients hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. We report the results of a prespecified analysis overall survival. randomly assigned HER2-negative cancer who had progression or relapse during previous endocrine therapy to receive palbociclib plus placebo fulvestrant. analyzed survival; effect according stratification factors presence absence sensitivity visceral metastatic disease, menopausal status; efficacy subsequent therapies after disease progression; safety. Among 521 underwent randomization, median was 34.9 months (95% confidence interval [CI], 28.8 40.0) palbociclib-fulvestrant group 28.0 CI, 23.6 34.6) placebo-fulvestrant (hazard ratio for death, 0.81; 95% 0.64 1.03; P=0.09; absolute difference, 6.9 months). CDK4/6 treatment completion trial regimen occurred 16% group. 410 39.7 34.8 45.7) 29.7 23.8 37.9) ratio, 0.72; 0.55 0.94; 10.0 duration similar two groups, time receipt chemotherapy 17.6 group, as compared 8.8 0.58; 0.47 0.73; P<0.001). No new safety signals were observed 44.8 follow-up. resulted longer than placebo-fulvestrant. differences entire not significant. (Funded by Pfizer; PALOMA-3 ClinicalTrials.gov number, NCT01942135 .).

Language: Английский

---

Liquid biopsy and minimal residual disease — latest advances and implications for cure

Nature Reviews Clinical Oncology, Journal Year: 2019, Volume and Issue: 16(7), P. 409 - 424

Published: Feb. 22, 2019

Language: Английский

---

The broken cycle: E2F dysfunction in cancer

Nature reviews. Cancer, Journal Year: 2019, Volume and Issue: 19(6), P. 326 - 338

Published: May 3, 2019

Language: Английский

---

Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019

Annals of Oncology, Journal Year: 2019, Volume and Issue: 30(10), P. 1541 - 1557

Published: Aug. 1, 2019

The 16th St. Gallen International Breast Cancer Conference 2019 in Vienna, Austria reviewed substantial new evidence on loco-regional and systemic therapies for early breast cancer.

Language: Английский

---

Resolving genetic heterogeneity in cancer

Nature Reviews Genetics, Journal Year: 2019, Volume and Issue: 20(7), P. 404 - 416

Published: March 27, 2019

Language: Английский

---

The emerging role of cell-free DNA as a molecular marker for cancer management

Biomolecular Detection and Quantification, Journal Year: 2019, Volume and Issue: 17, P. 100087 - 100087

Published: March 1, 2019

An increasing number of studies demonstrate the potential use cell-free DNA (cfDNA) as a surrogate marker for multiple indications in cancer, including diagnosis, prognosis, and monitoring. However, harnessing full cfDNA requires (i) optimization standardization preanalytical steps, (ii) refinement current analysis strategies, and, perhaps most importantly, (iii) significant improvements our understanding its origin, physical properties, dynamics circulation. The latter knowledge is crucial interpreting associations between changes baseline characteristics clinical manifestations cancer. In this review we explore recent advancements highlight gaps concerning each point contact different stages cancer management.

Language: Английский

---

Circulating tumor DNA and liquid biopsy in oncology

Nature Cancer, Journal Year: 2020, Volume and Issue: 1(3), P. 276 - 290

Published: March 20, 2020

Language: Английский

---

The lingering mysteries of metastatic recurrence in breast cancer

British Journal of Cancer, Journal Year: 2020, Volume and Issue: 124(1), P. 13 - 26

Published: Nov. 26, 2020

Despite being the hallmark of cancer that is responsible for highest number deaths, very little known about biology metastasis. Metastatic disease typically manifests after a protracted period undetectable following surgery or systemic therapy, owing to relapse recurrence. In case breast cancer, metastatic can occur months decades initial diagnosis and treatment. this review, we provide an overview key factors influence recurrence, with goal highlighting critical unanswered questions still need be addressed make difference in mortality patients.

Language: Английский

---

ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group

Annals of Oncology, Journal Year: 2022, Volume and Issue: 33(8), P. 750 - 768

Published: July 6, 2022

•Validated and sensitive ctDNA assays can be used to genotype advanced cancers select patients for targeted therapies.•Initial genotyping with should considered when rapid results are needed, tissue is unavailable.•ctDNA assay limited by false-negative results, lower sensitivity fusion events copy number changes.•Use of detect molecular residual disease not recommended, due lack evidence its clinical utility. Circulating tumour DNA (ctDNA) conducted on plasma rapidly developing a strong base use in cancer. The European Society Medical Oncology convened an expert working group review the analytical validity utility assays. For cancer, validated adequately have identifying actionable mutations direct therapy, may routine practice, provided limitations taken into account. Tissue-based testing remains preferred test many cancer patients, detecting changes, although routinely faster will clinically important, or biopsies possible inappropriate. Reflex following non-informative result, testing. In treated early-stage cancers, detection relapse, has high anticipating future relapse cancers. Molecular disease/molecular cannot recommended as currently there no directing treatment. Additional potential applications assays, under research development include responding therapy early dynamic changes levels, monitoring resistance before progression, screening asymptomatic people Recommendations reporting made.

Language: Английский

---

Liquid Biopsy: From Discovery to Clinical Application

Cancer Discovery, Journal Year: 2021, Volume and Issue: 11(4), P. 858 - 873

Published: April 1, 2021

Over the past 10 years, circulating tumor cells (CTC) and DNA (ctDNA) have received enormous attention as new biomarkers subjects of translational research. Although both are already used in numerous clinical trials, their utility is still under investigation with promising first results. Clinical applications include early cancer detection, improved staging, detection relapse, real-time monitoring therapeutic efficacy, targets resistance mechanisms. Here, we propose a conceptual framework CTC ctDNA assays point out current challenges research, which might structure this dynamic field SIGNIFICANCE: The analysis blood for CTCs or cell-free nucleic acids called "liquid biopsy" has opened avenues diagnostics, including tumors, risk assessment well relapse evolution context therapies.

Language: Английский

---